The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study
This study provides crucial insights for clinical practice and trial design. The distinct response patterns between progression groups suggest that early identification and balancing of RPs between groups could improve clinical trial efficiency. The findings support the development of personalized treatment approaches for rapid progressors, who have aggressive disease progression. These results may significantly modify clinical trial design and patient care in Alzheimer's disease.
Authors
- Kristofer Harris (ORCID: https://orcid.org/0000-0003-1250-6650)
- Matias Cattani
- Catherine Zhang
- Madison Shyer (ORCID: https://orcid.org/0000-0002-8166-1868)
- Dulin Wang (ORCID: https://orcid.org/0000-0003-1574-2093)
- Xiaoqian Jiang (ORCID: https://orcid.org/0000-0001-9933-2205)
- Paul Ernest Schulz (ORCID: https://orcid.org/0000-0003-0676-002X)
- Christine Farrell
- Elizabeth He
- Yejin Kim
Institutions
- The University of Texas Health Science Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1016/j.tjpad.2026.100483
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00